Certara (United States)

Modeling effective doses of therapeutic antibodies targeting clustered surface receptors

Abstract A longstanding practice for therapeutic dosing of monoclonal antibodies is to identify the maximally tolerated dose. However, this approach has encountered limited success with some antibodies, especially in failed cancer trials. Here we report on an alternative dose-fin...